Morocco • The inside story of Pharma Capital's acquisition of Servier Morocco

Anas Sefrioui’s Pharma Capital has outbid an offer from Moncef Belkhayat to acquire the Moroccan assets of French pharmaceutical group Servier, industry sources confirmed. The transaction, which transfers ownership of Servier’s local medicine portfolio and its Nouaceur production facility to Pharma Capital, remains conditional on approval by Morocco’s competition council.

"The pharmaceutical group owned by property magnate Anas Sefrioui has outbid Moncef Belkhayat to become the owner of French company Servier's Moroccan assets," industry briefings state. "The sale is however still subject to approval by the competition council."

Servier has been present in Morocco for around thirty years through a local subsidiary. The assets on offer included a portfolio of marketed medicines and the manufacturing site in Nouaceur, near Casablanca, which has been a key element in the negotiations. The deal marks another high-profile shift in Morocco’s domestic pharmaceutical landscape following recent consolidation moves by regional players.

Pharma Capital is controlled by Anas Sefrioui, a well-known Moroccan property magnate who has diversified into healthcare and pharmaceuticals. Moncef Belkhayat, the entrepreneur and politician who submitted a competing bid, had also been publicly linked with interest in Servier’s Moroccan portfolio earlier in the sales process. Sources indicate the sales process drew several suitors before converging on the Pharma Capital bid as the winning offer.

Deal specifics and local implications

• Assets: Servier’s Moroccan medicine portfolio and the Nouaceur production facility.
• Buyer: Pharma Capital, owned by Anas Sefrioui.
• Competing bidder: Moncef Belkhayat.
• Condition: Transaction subject to clearance by the competition council.

Sector observers say the acquisition could bolster Pharma Capital’s footprint in local manufacturing and distribution, aligning with broader industry trends of domestic consolidation and foreign asset transfers. The Nouaceur facility provides an operational manufacturing base that may accelerate local production capacity under new ownership. While financial terms were not disclosed publicly, the strategic value of the facility and marketed product lines makes the deal significant for Morocco’s pharmaceutical supply chain.

Local market watchers also note potential regulatory scrutiny. The sale must clear the competition council, which evaluates market concentration and antitrust risks. "The sale is however still subject to approval by the competition council," the announcement reiterated, underlining that the legal and regulatory process will determine the final timing and implementation of the transfer.

Outlook

If approved, the transaction will consolidate a sizeable portion of Servier’s Moroccan operations under domestic ownership, with potential impacts on employment at the Nouaceur site, local manufacturing volumes, and distribution arrangements for the acquired product portfolio. For competitors and healthcare stakeholders, the move will be watched closely for any shifts in pricing, supply continuity and local industrial strategy.

Regulatory proceedings before the competition council will be decisive. Stakeholders expect a formal review period during which the council may request remedies or conditions to safeguard competition. Until clearance is granted, Pharma Capital’s acquisition of Servier Morocco remains an agreed sale awaiting official regulatory endorsement.